The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Elmar Jaeckel is a medical doctor in the Department of Gastroenterology, Hepatology & Endocrinology at the Hannover Medical School, Hannover, Germany. He received his training in Hamburg, Germany; Yale New Haven, New Haven, CT, USA; the University of California San Diego, CA, USA; the University of Edinburgh, Edinburgh, UK; and the University of Sydney, Sydney, Australia. Dr Jaeckel spent 4 years as a postdoctoral fellow at the Joslin Diabetes Center of the Harvard Medical School, Boston, MA, USA. He is the attending endocrinologist and diabetologist at the Hannover Medical School.
Dr Jaeckel’s working group, Immune Tolerance, aims to establish immune tolerance in type 1 diabetes and after biological beta-cell replacement. For this purpose, he is developing new cell and gene therapy approaches. Dr Jaeckel is involved in pursuing islet xenotransplantation in Germany. He is also studying non-alcoholic steatohepatitis (NASH) in animal models and patient material and is developing incretin-based therapies for NASH.
Lise Lotte Gluud
University of Copenhagen, Copenhagen, Denmark
Professor Lise L Gluud is a consultant gastroenterologist and professor of gastroenterology and hepatology. Her main research areas include lifestyle-associated liver diseases focusing on non-alcoholic steatohepatitis as well as cirrhosis-related complications. Other areas of interest include inflammatory and metabolic complications associated with pancreatitis. Professor Gluud is a member of the European Foundation for the Study of Chronic Liver Failure Steering Committee, and the national representative in the Prospective European Drug-Induced Liver Injury Network Management Committee.
Other qualifications include: Specially Appointed Named Person at the Faculty of Health and Medical Sciences, University of Copenhagen, Member of the National Committee on Health Research Ethics; Chairman of the National Clinical Guideline for the management of patients with non-alcoholic fatty liver disease; Chairman of the Danish Association of Gastroenterology and Hepatology (DSGH) Guideline Committee; Member of DSGH Research Committee; PLoS One Section Editor; and Editor Cochrane Hepato-Biliary Group.